JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB264734

Human NRG4 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

NRG4 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 1 bp insertion in exon 3 and 2 bp deletion in exon 3.

View Alternative Names

DKFZp779N0541, DKFZp779N1944, HRG4, Heregulin 4, NRG4_HUMAN, Neuregulin-4, Pro-NRG4, pro-neuregulin-4, membrane-bound isoform

3 Images
Sanger Sequencing - Human NRG4 knockout HeLa cell line (AB264734)
  • Sanger seq

Unknown

Sanger Sequencing - Human NRG4 knockout HeLa cell line (AB264734)

Allele-1 : 2 bp deletion in exon 3.

Sanger Sequencing - Human NRG4 knockout HeLa cell line (AB264734)
  • Sanger seq

Unknown

Sanger Sequencing - Human NRG4 knockout HeLa cell line (AB264734)

Allele-2 : 1 bp deletion in exon 3.

Sanger Sequencing - Human NRG4 knockout HeLa cell line (AB264734)
  • Sanger seq

Unknown

Sanger Sequencing - Human NRG4 knockout HeLa cell line (AB264734)

Allele-3 : 1 bp insertion in exon 3.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 1 bp insertion in exon 3 and 2 bp deletion in exon 3

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264734-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264734 Human NRG4 knockout HeLa cell line", "number":"AB264734-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab264734-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab264734 Human NRG4 knockout HeLa cell line", "number":"AB264734-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
NRG4
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

Neuregulin 4 (NRG4) is a member of the neuregulin family. It functions as a signaling molecule with a role in cell communication. NRG4 weighs approximately 40 kDa and mainly expresses in adipose tissue and the brain. It binds to erythroblastic leukemia viral oncogene homolog (ErbB) family receptors especially ErbB4 to execute its functions. These bindings initiate a cascade of intracellular events impacting various cellular activities.
Biological function summary

The protein NRG4 plays a significant role in regulating energy metabolism and maintaining homeostasis. It is not part of a complex but as a ligand it interacts directly with its receptor ErbB4. NRG4 activity helps regulate liver lipid metabolism preventing excessive lipid accumulation. Furthermore NRG4 involvement extends to pancreatic function where it aids in preserving insulin sensitivity with implications for glucose homeostasis.

Pathways

The protein NRG4 acts within the ErbB signaling pathway which is critical for cellular growth and differentiation. In this pathway NRG4 enhances the proliferation and differentiation of cells by activating the ErbB4 receptor. NRG4 also interfaces with the PI3K/AKT pathway playing a role in metabolic processes and cellular survival. The interaction with ErbB4 signifies its relation to other neuregulin proteins like NRG1 which also engage this receptor family showcasing their coordinated impact on metabolic regulation.

The protein NRG4 has links to metabolic disorders such as obesity and type 2 diabetes. Lower levels of NRG4 correlate with increased risk of these conditions highlighting its importance in metabolic health. NRG4 also interacts with inflammatory cytokines in the context of obesity where an imbalance can exacerbate metabolic dysregulation. Additionally in type 2 diabetes the target's association with insulin sensitivity indicates a therapeutic potential alongside its interactive partner ErbB4.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com